Cipro XR Shortage: What Providers and Prescribers Need to Know in 2026

Patients presenting with UTIs or pyelonephritis may ask about or already be prescribed Cipro XR, only to find it unavailable at their pharmacy. This provider brief summarizes the current availability landscape, evidence-based alternatives, and practical resources to help your patients access effective antibiotic therapy without delay.

Current Cipro XR Availability Status (2026)

Brand-name Cipro XR (ciprofloxacin extended-release, Bayer) has been discontinued and is no longer commercially available. Proquin XR (Depomed), a once-daily ciprofloxacin ER formulation for uncomplicated UTIs, was similarly discontinued. As of 2026:

There is NO active FDA-declared shortage of ciprofloxacin extended-release.

Generic ciprofloxacin ER (500 mg and 1000 mg) is available from multiple manufacturers.

Pharmacy stocking is inconsistent — many retail pharmacies do not carry the ER formulation routinely.

Immediate-release ciprofloxacin tablets (250 mg, 500 mg, 750 mg) remain widely available at virtually all pharmacies.

Practical implication: patients prescribed Cipro XR by brand name will encounter difficulty filling their prescription. Prescribing generic ciprofloxacin ER by its generic name and strength, or switching to an alternative, reduces patient burden.

Prescribing Note: Cipro XR vs. Immediate-Release Are Not Interchangeable

The FDA explicitly notes that Cipro XR and immediate-release ciprofloxacin tablets are NOT interchangeable. The extended-release formulation uses a bilayer matrix that releases a portion of the drug rapidly and the remainder slowly over 24 hours, achieving higher peak plasma concentrations than the equivalent immediate-release BID doses while maintaining equivalent AUC over 24 hours. A pharmacist cannot automatically substitute one for the other — prescriber authorization is required for any formulation change.

FDA-Approved Indications for Ciprofloxacin Extended-Release

Uncomplicated UTI (acute cystitis): Caused by E. coli, Proteus mirabilis, Enterococcus faecalis, or Staphylococcus saprophyticus — 500 mg QD x 3 days

Complicated UTI and acute uncomplicated pyelonephritis: 1000 mg QD x 7-14 days; reduce to 500 mg QD if CrCl ≤30 mL/min

FDA Black Box Warning: Clinical Implications

Ciprofloxacin (including the ER formulation) carries an FDA Black Box Warning for potentially disabling and irreversible serious adverse reactions, including:

Tendinitis and tendon rupture (risk elevated in patients >60 years, concurrent corticosteroid use, organ transplant recipients)

Peripheral neuropathy (may be permanent; discontinue immediately if symptoms develop)

CNS effects: seizures, toxic psychosis, hallucinations, depression (risk elevated with NSAIDs, history of seizure disorders)

Exacerbation of myasthenia gravis (avoid in patients with known MG)

Aortic aneurysm/dissection (increased risk; caution in elderly patients and those with cardiovascular risk factors)

The FDA has specifically stated that fluoroquinolones should be reserved for use when no alternative treatment options are available for uncomplicated UTIs. This guidance underscores the importance of first-line antibiotic stewardship.

Evidence-Based Alternatives to Cipro XR for UTI and Pyelonephritis

For Uncomplicated UTI (Acute Cystitis):

TMP-SMX (Bactrim DS) 160/800 mg BID x 3 days — first-line per IDSA guidelines if local resistance <20%

Nitrofurantoin (Macrobid) 100 mg BID x 5-7 days — first-line; avoid if eGFR <30 mL/min/1.73m²

Fosfomycin (Monurol) 3 g single dose — convenient, well-tolerated, lower resistance rates

For Complicated UTI or Acute Uncomplicated Pyelonephritis:

Levofloxacin 750 mg QD x 5-7 days — comparable efficacy to ciprofloxacin in randomized controlled trials

Ciprofloxacin IR 500 mg BID x 7-10 days — same active ingredient as Cipro XR, widely available

TMP-SMX 1 DS tablet BID x 14 days — appropriate if susceptibility confirmed by urine culture

Key Drug Interactions to Review Before Prescribing

If you do prescribe ciprofloxacin ER, review these clinically significant interactions:

Tizanidine: Contraindicated — ciprofloxacin markedly increases tizanidine plasma levels, causing severe hypotension and sedation

Theophylline: Monitor levels closely; ciprofloxacin inhibits CYP1A2, increasing theophylline toxicity risk

Warfarin: Increased anticoagulant effect; monitor INR closely

Antacids/multivalent cations: Significantly reduce absorption; instruct patients to separate by 2 hours before or 6 hours after

QT-prolonging agents: Additive QT prolongation risk; use caution and consider ECG monitoring

Helping Patients Access Ciprofloxacin ER

When prescribing ciprofloxacin ER, consider these steps to minimize patient fill delays:

Write the prescription as 'ciprofloxacin extended-release' with the specific strength — not 'Cipro XR' which pharmacy systems may flag as discontinued

Direct patients to call ahead to confirm pharmacy stock before presenting the prescription

Refer patients to medfinder for Providers to check real-time pharmacy availability in their area

Consider adding a note of medical necessity for uncommon formulations if prior authorization is required

Summary for Providers

Cipro XR brand is discontinued. Generic ciprofloxacin ER remains commercially available but is inconsistently stocked. Given the FDA's Black Box Warning recommending fluoroquinolone reserve status for UTIs, consider whether first-line alternatives (TMP-SMX, nitrofurantoin) are appropriate before prescribing. If ciprofloxacin ER is clinically necessary, prescribe by generic name and prepare patients for the possibility of calling multiple pharmacies. For the patient-facing version of this update, see our Cipro XR shortage update for patients.